Target Name: FTMT
NCBI ID: G94033
Review Report on FTMT Target / Biomarker Content of Review Report on FTMT Target / Biomarker
FTMT
Other Name(s): Ferritin, mitochondrial | Mitochondrial ferritin | ferritin H subunit | mitochondrial ferritin | ferritin mitochondrial | MTF | OTTHUMP00000159158 | Ferritin mitochondrial | FTMT_HUMAN

A Promising Approach to treat Anemia and Myopathies: Ferritin, Mitochondrial, and Its Potential as a Drug Target

Introduction

Anemia and myopathies are common disorders that affect millions of people worldwide, leading to significant morbidity and economic costs. The two conditions, in addition to other diseases, have a significant impact on an individual's quality of life and overall health. There is a growing interest in finding new treatments and approaches to alleviate these conditions, and one promising candidate is ferritin, a protein produced by the body that is known to be a biomarker for anemia and myopathies. In this article, we will explore the potential of ferritin as a drug target and its potential as a treatment for anemia and myopathies.

Ferritin: A protein produced by the body

Ferritin is a protein produced by the body that is primarily found in red blood cells, the most abundant type of blood cell in the body. It is a protein that is composed of four subunits, each of which has a different function in the production of hemoglobin. Ferritin is the protein that is responsible for carrying oxygen in the blood from the lungs to the rest of the body. It does this by forming a complex with hemoglobin, which is the protein that is responsible for carrying oxygen in the blood from the lungs to the rest of the body.

Ferritin is also involved in the regulation of inflammation in the body. It has been shown to have anti-inflammatory properties and to play a role in the immune response. In addition, ferritin has also been shown to have neuroprotective properties, which may have implications for the treatment of neurodegenerative diseases.

Potential as a drug target

Ferritin has been identified as a potential drug target for the treatment of anemia and myopathies due to its unique structure and its involvement in several biological processes that are associated with these conditions.

Anemia is a condition in which there is a decrease in the number of red blood cells or the amount of hemoglobin in the blood. This can lead to fatigue, weakness, and other serious health consequences. Ferritin has been shown to have the potential to treat anemia by increasing the production of hemoglobin in the body. Studies have shown that administering ferritin to patients with anemia can lead to an increase in the number of red blood cells and an improvement in the symptoms associated with anemia.

Myopathies are a group of diseases that are characterized by muscle weakness and dysfunction. These conditions can be caused by a variety of factors, including genetic mutations, infections, and certain medications. Ferritin has also been shown to have the potential to treat myopathies by increasing the production of muscle protein in the body. Studies have shown that administering ferritin to patients with myopathies can lead to an improvement in muscle strength and function.

Other potential benefits of ferritin as a drug target include its anti-inflammatory properties and its neuroprotective properties. Ferritin has been shown to have anti-inflammatory properties, which may help to reduce the risk of chronic inflammation and the development of other inflammatory conditions. In In addition, ferritin has also been shown to have neuroprotective properties, which may help to protect against the effects of neurodegenerative diseases.

Conclusion

In conclusion, ferritin is a protein that is produced by the body that has been shown to have a number of potential benefits as a drug target. Its unique structure and its involvement in several biological processes make it an attractive candidate for the treatment of anemia and myopathies. Further research is needed to fully understand the potential of ferritin as a drug target and to determine its safety and effectiveness in clinical trials.

Protein Name: Ferritin Mitochondrial

Functions: Catalyzes the oxidation of ferrous iron(II) to ferric iron(III) and stores iron in a soluble, non-toxic, readily available form (PubMed:11323407, PubMed:15201052). Important for iron homeostasis (PubMed:11323407, PubMed:15201052). Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation (PubMed:11323407, PubMed:15201052)

The "FTMT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FTMT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

FTO | FTO-IT1 | FTOP1 | FTSJ1 | FTSJ3 | FTX | FUBP1 | FUBP3 | FUCA1 | FUCA2 | Fucosyl GM1 | Fucosyltransferase | FUNDC1 | FUNDC2 | FUNDC2P2 | FUNDC2P3 | FUOM | FURIN | FUS | FUT1 | FUT10 | FUT11 | FUT2 | FUT3 | FUT4 | FUT5 | FUT6 | FUT7 | FUT8 | FUT8-AS1 | FUT9 | FUZ | FXN | FXR1 | FXR2 | FXYD1 | FXYD2 | FXYD3 | FXYD4 | FXYD5 | FXYD6 | FXYD6-FXYD2 | FXYD7 | FYB1 | FYB2 | FYCO1 | FYN | FYTTD1 | FZD1 | FZD10 | FZD10-AS1 | FZD2 | FZD3 | FZD4 | FZD4-DT | FZD5 | FZD6 | FZD7 | FZD8 | FZD9 | FZR1 | G protein-Coupled Inwardly-Rectifying Potassium Channel (GIRK) | G Protein-Coupled Receptor Kinases (GRKs) | G0S2 | G2E3 | G2E3-AS1 | G3BP1 | G3BP2 | G6PC1 | G6PC2 | G6PC3 | G6PD | GA-binding protein | GAA | GAB1 | GAB2 | GAB3 | GAB4 | GABA(A) receptor | GABARAP | GABARAPL1 | GABARAPL2 | GABARAPL3 | GABBR1 | GABBR2 | GABPA | GABPAP | GABPB1 | GABPB1-AS1 | GABPB1-IT1 | GABPB2 | GABRA1 | GABRA2 | GABRA3 | GABRA4 | GABRA5 | GABRA6 | GABRB1 | GABRB2 | GABRB3